Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma
Authors
Keywords
Antibody-drug conjugate, CD70, SGN-75, Renal cell carcinoma, Non-Hodgkin lymphoma, Phase I clinical trial
Journal
INVESTIGATIONAL NEW DRUGS
Volume 32, Issue 6, Pages 1246-1257
Publisher
Springer Nature
Online
2014-08-21
DOI
10.1007/s10637-014-0151-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Potent Anti-CD70 Antibody–Drug Conjugate Combining a Dimeric Pyrrolobenzodiazepine Drug with Site-Specific Conjugation Technology
- (2013) Scott C. Jeffrey et al. BIOCONJUGATE CHEMISTRY
- CD27 Signaling Increases the Frequency of Regulatory T Cells and Promotes Tumor Growth
- (2012) C. Claus et al. CANCER RESEARCH
- The CD27 and CD70 Costimulatory Pathway Inhibits Effector Function of T Helper 17 Cells and Attenuates Associated Autoimmunity
- (2012) Jonathan M. Coquet et al. IMMUNITY
- Phase I Multidose-Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/Refractory B-Cell Lymphoma
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
- (2012) Barbara Pro et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody–drug conjugate SGN-75
- (2010) M C Ryan et al. BRITISH JOURNAL OF CANCER
- Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
- (2010) Anas Younes et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Pharmacologic Basis for Antibody-Auristatin Conjugate Activity
- (2009) S. C. Alley et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia
- (2008) A. W. Ho et al. BLOOD
- Potent Anticarcinoma Activity of the Humanized Anti-CD70 Antibody h1F6 Conjugated to the Tubulin Inhibitor Auristatin via an Uncleavable Linker
- (2008) E. Oflazoglu et al. CLINICAL CANCER RESEARCH
- Preclinical Characterization of SGN-70, a Humanized Antibody Directed against CD70
- (2008) J. A. McEarchern et al. CLINICAL CANCER RESEARCH
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- CD70 as a therapeutic target in human malignancies
- (2008) Iqbal S Grewal EXPERT OPINION ON THERAPEUTIC TARGETS
- Autoimmune thrombocytopenia in non-Hodgkin's lymphomas
- (2008) A. W. Hauswirth et al. HAEMATOLOGICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now